Skip to content

    Aurobindo Pharma

    AUROPHARMA
    Healthcare·27 May 2025
    Management Summary

    Aurobindo Pharma delivered its highest-ever revenues and EBITDA in Q4 and full year FY25, driven by strong performance across US and European formulation businesses, and improved gross margins. The company transitioned from a net debt to a net cash surplus, reflecting robust cash flow generation. Strategic capacity expansions in China and the US are underway, with biosimilars poised for double-digit growth from next fiscal year, despite some near-term headwinds from the Pen-G plant incident and muted injectable growth in FY26.

    Highlights

    9
    • FY25 revenues of Rs. 31,724 crores and EBITDA of Rs. 6,605 crores (20.8% margin) represent highest ever figures.

    • Q4 FY25 revenues of Rs. 8,382 crores and EBITDA of Rs. 1,792 crores (21.4% margin) also represent highest ever figures.

    • Gross margins for Q4 FY25 increased by 65 basis points quarter-on-quarter to 59.1%, supported by favorable product mix and benign raw material prices.

    • Net profit for Q4 FY25 increased by 7% quarter-on-quarter to Rs. 903 crores.

    • Cash flows improved significantly, resulting in a net cash surplus of US$ 42 million as of March 31, 2025.

    • US formulation revenue grew 13% year-on-year to Rs. 4,072 crores (US$ 470 million) in Q4 FY25.

    • European formulation revenue grew 17% year-on-year to Rs. 2,147 crores (€236 million) in Q4 FY25.

    • ARV business increased by 29% year-on-year to Rs. 308 crores (US$ 36 million) in Q4 FY25.

    • Specialty and Injectable global business revenue increased by 25% year-on-year to US$ 178 million in Q4 FY25.

    Concerns

    6
    • One-time recurring expenses, including fuel/power adjustments, inventory provisions, and corporate development costs, had a negative impact of over Rs. 105 crores.

    • PLI facilities contributed a negative Rs. 30 crores plus at the EBITDA level.

    • Other income in Q4 FY25 was lower at Rs. 123 crores compared to Rs. 143 crores in Q3 FY25 and Rs. 153 crores in Q4 FY24.

    • The China plant incurred a loss of around Rs. 35 crore plus in its first year (FY25).

    • Injectable business growth for FY26 is expected to be muted due to Eugia-3 remediation issues and absence of a 'superstar product'.

    • Revlimid sales for FY26 are projected to be less than FY25.

    What Changed2

    vs Q1 FY26

    Guidance items13 → 19 (+6)Risks discussed4 → 5 (+1)
    Key financials

    Metrics

    11

    Periods

    4

    Q4 FY25

    5
    • Revenue
      ₹8,382 Cr
      YoY+11%QoQ+5%
    • EBITDA
      ₹1,792 Cr
      YoY+6%QoQ+10%
    • EBITDA Margin
      21.4%
    • Net Profit
      ₹903 Cr
      QoQ+7.0%
    • R&D Spend
      ₹423 Cr

    FY25

    4
    • Revenue
      ₹31,724 Cr
      YoY+9%
    • EBITDA
      ₹6,605 Cr
    • EBITDA Margin
      20.8%
    • R&D Spend
      ₹1,622 Cr

    % of Revenue FY25

    1
    • R&D Spend
      5.1%

    % of Revenue Q4 FY25

    1
    • R&D Spend
      5%

    Segment breakdown

    Revenue (Q4 FY25)Revenue (FY25)Revenue (Q4 FY25, Constant Currency)
    Formulation Business₹7,313 Cr₹27,388 Cr
    API Business₹1,069 Cr₹4,323 Cr
    USA Formulation₹4,072 Cr₹14,816 Cr470 Mn
    Europe Formulation₹2,147 Cr₹8,356 Cr236 Mn
    Growth Market91 Mn
    ARV Business₹308 Cr₹1,037 Cr36 Mn
    Specialty and Injectable Global Business178 Mn
    Heatmap· 3 shared metrics

    Capital allocation

    3
    high confidence
    CategoryHeadline
    Capex

    USD 90 million

    Debt

    Net USD 42 million

    Cost 5.5%

    Liquidity

    Cash USD 42 million

    Net cash surplus position achieved from a net debt position.

    Guidance & targets

    18
    CategoryTargetPriority
    Revenue
    Revenue Growth
    high single-digit
    High
    Revenue
    China OSD Plant Revenue Contribution
    contribute revenues
    High
    Revenue
    Europe Revenue Growth
    8-9%
    High
    Revenue
    Europe Revenue
    past billion-dollar mark
    High
    Revenue
    Revlimid Sales
    less than FY25
    High
    Profitability
    EBITDA Margin
    maintain present levels
    High
    Profitability
    China Plant Profitability
    break-even or slightly positive
    High
    Capacity
    Dayton US OSD Plant Commercialization
    commercialized
    High
    Growth
    Injectables Growth
    muted
    High
    Growth
    Injectables Growth
    great year
    High
    Biosimilars
    Inflection Year
    2028
    High
    Biosimilars
    Revenue
    US$ 250-400 million
    Medium
    Production
    Pen-G Plant Production in Guidance
    6-8 months
    High
    Other Income
    Other Operating Income
    around 200 crores plus
    High
    Tax Rate
    Consolidated Tax Rate
    28-30%
    High
    CDMO
    TheraNym Plant Commissioning
    Q2
    High
    CDMO
    TheraNym Validation Batches
    Q4
    High
    CDMO
    TheraNym Revenues
    coming in
    High

    Pen-G Plant Restart & Production

    next quarter
    CurrentOperations halted, awaiting PCB approval
    TargetProduction resumed, PCB approval received

    Why it matters

    Essential for realizing the potential of the Pen-G PLI project and its contribution to EBITDA.

    The production will resume promptly upon receiving the necessary approvals to avoid any undue risks.

    How to verify

    risks_and_concerns[risk='Pen-G facility fire incident and operational halt']

    Risks & concerns

    5
    RiskSeverity

    Pen-G facility fire incident and operational halt

    A fire incident at the Penicillin-G facility in Kakinada caused an estimated impact of Rs. 4 crores and led to a temporary halt in operations, awaiting regulatory approvals for resumption.Management acknowledged

    medium

    Eugia-3 remediation issues impacting injectable growth

    The Eugia-3 facility is yet to be cleared, leading to a muted growth outlook for the injectable business in FY26, with significant launches pushed to FY27.Analyst acknowledged

    medium

    Impact of upcoming tariff announcements

    Tariff announcements expected in July '25 could potentially impact the business, though management does not anticipate a major impact.Management acknowledged

    medium

    Losses from new China OSD plant in initial year

    The China OSD plant incurred a loss of over Rs. 35 crores in its first year (FY25), though it is expected to break-even or turn slightly positive in FY26.Management acknowledged

    low

    Decline in Revlimid sales in FY26

    Revlimid sales for FY26 are projected to be lower than FY25, which will impact overall revenue.Management acknowledged

    medium

    Q&A highlights

    8

    “normally, we don't comment on Revlimid sales or units or value. But yeah, like in fact, we have done whatever we planned to do. And we are only left with balance for the next year. But beyond that, I think I won't be in a position to comment in terms of the numbers. We haven't. In fact, like nothing has spilled from Q4 to the next year. It is just as planned.”

    Analyst probed for specific Revlimid sales figures and future trajectory, which management declined to provide, indicating sensitivity around this key product's performance.

    asked by Damayanti Kerai

    3 min read6 chapters

    Detailed Narrative

    01

    Strong Financial Performance in Q4 and Full Year FY25

    Aurobindo Pharma achieved its highest-ever revenues and EBITDA for both Q4 and the full fiscal year 2025. For FY25, revenues reached ₹31,724 crores, with an EBITDA of ₹6,605 crores, translating to a 20.8% margin. Q4 FY25 saw revenues of ₹8,382 crores and EBITDA of ₹1,792 crores, with a robust 21.4% margin. Gross margins improved by 65 basis points quarter-on-quarter to 59.1%, driven by a favorable product mix and benign raw material prices, despite one-time📎 expenses exceeding ₹105 crores.

    02

    Robust Growth Across Key Business Segments

    The formulation business, contributing 87% of total revenue, grew 12% year-on-year to ₹7,313 crores in Q4 FY25, primarily fueled by strong performance in the US and Europe. US formulation revenue increased 13% year-on-year to ₹4,072 crores (US$ 470 million), while European formulation revenue grew 17% year-on-year to ₹2,147 crores (€236 million). The API business also saw a 5% year-on-year growth to ₹1,069 crores in Q4 FY25, driven by higher volumes and improved asset utilization. The ARV business notably grew 29% year-on-year to ₹308 crores (US$ 36 million).

    03

    Strategic Capacity Expansion and New Market Entry

    Aurobindo is actively expanding its manufacturing footprint, with formulation capacity now exceeding 60 billion units. The China OSD plant, commercialized this year with 2 billion units capacity, is expected to contribute revenues in FY26 and aims for break-even or slight profitability. The US-based OSD plant at Dayton is also slated for commercialization during FY26, while the Raleigh facility is expected to be fully operational soon to include transdermal and respiratory products. The company is also developing multiple respiratory products, partnering with a global pharma major in FY25.

    04

    Biosimilars and Complex Products: Long-term Growth Drivers

    The company has made a significant cumulative investment of over US$ 400 million in its biosimilar business. Following recent European approvals and a positive opinion for Dazublys, Aurobindo plans to commence supplies from Q2 of the next fiscal year. Management projects double-digit revenue growth for the biosimilar business starting next fiscal, with 2028 anticipated as the inflection year. By 2030-31, the biosimilar business is expected to generate US$ 250-400 million in revenues from approximately seven products in regulated markets.

    05

    Pen-G Plant Incident and PLI Scheme Update

    A fire incident at the Penicillin-G facility in Kakinada resulted in an estimated impact of ₹4 crores and a temporary halt in operations. Rectification efforts are complete, and the company is awaiting regulatory approvals from the PCB to resume production. Management emphasized that running the PLI-supported plant at full capacity is crucial for achieving profitability, noting that PLI facilities contributed a negative ₹30 crores to EBITDA in FY25. Discussions around minimum import prices for critical raw materials are ongoing, which could potentially benefit the project.

    06

    Improved Capital Structure and FY26 Outlook

    Aurobindo Pharma significantly strengthened its capital structure, moving from a net debt of US$ 84 million as of December 31, 2024, to a net cash surplus of US$ 42 million by March 31, 2025, driven by improved working capital. The average finance cost for the period was 5.5%. For FY26, the company targets high single-digit revenue growth (excluding transient📎 products) and aims to maintain current EBITDA margins. While injectable growth is expected to be muted in FY26 due to Eugia-3 remediation, FY27 is projected to be a strong year with significant launches and settlement-based products.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.